4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001209191-17-063927
Chief Executive Officer sold 6,000 shares at an average $61.55 ($369,288)
- Chief Executive Officer acquired 6,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Schenkein David P Chief Executive Officer | 2017-12-01 | Option exercise | +6,000 | $0.30 | $1,815 | 6,000 | D: show line 1 in the form |
| Schenkein David P Chief Executive Officer | 2017-12-01 | Sale | −5,600 | $61.51 | $344,456 | 400 | D: show line 2 in the form |
| Schenkein David P Chief Executive Officer | 2017-12-01 | Sale | −400 | $62.08 | $24,832 | 0 | D: show line 3 in the form |
| Open-market sales · 6,000 sh · avg $61.55 · $369,288 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Schenkein David P Chief Executive Officer | 2017-12-01 | Option exercise · Stock option (right to buy) | −6,000 | 20,656 | D: show line 4 in the form |
Loading xslF345X03/doc4.xml…